Literature DB >> 9224700

Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains.

C Russo1, T C Saido, L M DeBusk, M Tabaton, P Gambetti, J K Teller.   

Abstract

Water-soluble amyloid beta-peptides (sA beta), ending at residue 42, precede amyloid plaques in Down's syndrome (DS). Here we report that sA beta consists of the full-length A beta(1-42) and peptides truncated and modified by cyclization of the N-terminal glutamates, A beta[3(pE)-42] and A beta[11(pE)-42]. The A beta[3(pE)-42] peptide is the most abundant form of sA beta in Alzheimer's disease (AD) brains. In DS, sA beta[3(pE)-42] concentration increases with age and the peptide becomes a dominant species in the presence of plaques. Both pyroglutamate-modified peptides and the full-length A beta form a stable aggregate that is water soluble. The findings point to a crucial role of the aggregated and modified sA beta in the plaque formation and pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224700     DOI: 10.1016/s0014-5793(97)00564-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  39 in total

1.  The enterins: a novel family of neuropeptides isolated from the enteric nervous system and CNS of Aplysia.

Authors:  Y Furukawa; K Nakamaru; H Wakayama; Y Fujisawa; H Minakata; S Ohta; F Morishita; O Matsushima; L Li; E Romanova; J V Sweedler; J H Park; A Romero; E C Cropper; N C Dembrow; J Jing; K R Weiss; F S Vilim
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

2.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Authors:  Caty Casas; Nicolas Sergeant; Jean-Michel Itier; Véronique Blanchard; Oliver Wirths; Nicolien van der Kolk; Valérie Vingtdeux; Evita van de Steeg; Gwenaëlle Ret; Thierry Canton; Hervé Drobecq; Allan Clark; Bruno Bonici; André Delacourte; Jesús Benavides; Christoph Schmitz; Günter Tremp; Thomas A Bayer; Patrick Benoit; Laurent Pradier
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

3.  Amyloid-beta peptide Abetap3-42 affects early aggregation of full-length Abeta1-42.

Authors:  Hiromi M Sanders; Robert Lust; Jan K Teller
Journal:  Peptides       Date:  2009-02-11       Impact factor: 3.750

4.  Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

Authors:  C Russo; G Angelini; D Dapino; A Piccini; G Piombo; G Schettini; S Chen; J K Teller; D Zaccheo; P Gambetti; M Tabaton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Authors:  Alex E Roher; Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Jesse M Hunter; Marwan N Sabbagh; Thomas G Beach
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 6.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

7.  Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.

Authors:  Jessica L Wittnam; Erik Portelius; Henrik Zetterberg; Mikael K Gustavsson; Stephan Schilling; Birgit Koch; Hans-Ulrich Demuth; Kaj Blennow; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2012-01-20       Impact factor: 5.157

8.  Steroids as γ-secretase modulators.

Authors:  Joo In Jung; Thomas B Ladd; Thomas Kukar; Ashleigh R Price; Brenda D Moore; Edward H Koo; Todd E Golde; Kevin M Felsenstein
Journal:  FASEB J       Date:  2013-05-28       Impact factor: 5.191

9.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

10.  Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.

Authors:  Oliver Wirths; Henning Breyhan; Holger Cynis; Stephan Schilling; Hans-Ulrich Demuth; Thomas A Bayer
Journal:  Acta Neuropathol       Date:  2009-06-23       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.